Search

Syncore Biotechnology Pancreatic Cancer Treatment Patent EP3565530A1

The European Patent Office has published patent application EP3565530A1 by Syncore Biotechnology Co., Ltd., covering compositions and methods for treating refractory or multidrug resistant pancreatic cancer. The application claims therapeutic combinations including chemotherapy agents (A61K 31/337, A61K 31/7068) in liposomal formulations (A61K 9/127). This publication applies to 38 designated European Contracting States and establishes the application as published prior art.

Treatment of Fuchs' Endothelial Corneal Dystrophy - Patent EP3592365A1

The European Patent Office granted patent EP3592365A1 to the University of Texas System and University of Massachusetts Medical School on April 8, 2026, covering oligonucleotide compositions for treating Fuchs' Endothelial Corneal Dystrophy. The patent is designated for all European patent states including DE, FR, GB, IT, NL, ES, and 26 others.

Lactobacillus Fermentum Treats Fructose-Related Diseases (EP3768286A1)

EPO published patent application EP3768286A1 on April 8, 2026, covering Lactobacillus fermentum compositions for treating fructose-related diseases. The patent names AixSwiss B.V. as applicant and lists PAULE, Jörg and OESTER, Fabio as inventors. The designation covers 31 European states including all major EU markets.

Tripentadecanoin for Use in Treatment of Retinal or Optic Nerve Degenerative Disease

The European Patent Office published patent application EP3468551A1 for SunRegen Healthcare AG, covering tripentadecanoin for use in treating retinal degenerative diseases or optic nerve degenerative diseases. The patent names DONG Yuhong, CHANG Chun-Hsiung, and LIN Shengtang as inventors. The application is classified under A61K (medicinal preparations) and A61P (therapeutics) with designations extending across 32 European member states.

Overtape Transdermal Delivery System Patent - AdhexPharma

The European Patent Office (EPO) published patent application EP3412283A1 for AdhexPharma SAS covering an overtape for a transdermal delivery system. The patent is designated for all European member states and several additional countries. IPC classifications indicate the technology relates to analgesics (A61P 25/04) and transdermal pharmaceutical delivery (A61K 9/70).

Process for Preparing Cannabinoid-Containing Oral Pharmaceutical Composition

The European Patent Office granted Patent EP3351242A1 to Prati, Donaduzzi & Cia LTDA and Universidade De São Paulo for a process preparing a cannabinoid-containing oral pharmaceutical composition. The patent covers compositions for treating neurological and psychiatric conditions including seizures, Parkinson's disease, and anxiety disorders. The oral formulation can be delivered as a liquid, softgel, or powder.

Therapeutic Combinations Comprising Anti-FOLR1 Immunoconjugates

EPO published patent application EP3349796A1 for ImmunoGen, Inc., covering therapeutic combinations of anti-FOLR1 immunoconjugates for cancer treatment. The A1 publication indicates the application has passed EPO's search examination and is now publicly available. The patent covers compositions including the novel ADC candidate targeting folate receptor alpha (FOLR1), a validated cancer antigen, along with combination therapies using cytotoxins and additional anticancer agents.

Peptide Amide Composition for Kappa Opioid Receptor Treatment

USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.

Cytotoxic Imidazopyridine Compounds and Their Use in Therapy

The USPTO granted Patent US12599676B2 to MyricX Pharma Limited for cytotoxic imidazo[1,2-A]pyridine compounds and their therapeutic use. The patent covers compounds of formula (I) classified under A61P 35/00 for cancer therapy. The application (19072750) was filed March 6, 2025, and the patent contains 23 claims.

Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells

USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.